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S U M M A R Y
Objectives: HIV-infected women are at increased risk of human papillomavirus (HPV) infection. Time
trends in annual prevalences of cervical high-risk human papillomavirus (HR-HPV) genotypes among a
non-vaccinated, HIV-infected female cohort in urban Brazil were assessed for the period 2006–2012.
Methods: Cervical specimens were collected for HPV genotyping yearly between January 2006 and
December 2012 in a cross-sectional analysis of participants aged 18 years enrolled in the Women’s HIV
Cohort at Fiocruz in Rio de Janeiro, Brazil. Age-adjusted generalized estimating equation models with an
exchangeable matrix were used to estimate odds ratios (OR) and 95% conﬁdence intervals (CI) for annual
HPV positivity (reference year: 2006).
Results: Among the 590 participants, the median age across all study years ranged from 35.5 to
40.0 years. The prevalence of any HR-HPV was 53% every year; prevalences of HR-HPV 16, 58, 59, and
68 were 24% in at least 1 year. The odds of HPV 16 and 68 decreased in 2012. HPV 58 prevalence
followed a U-shape, beginning and ending at >20%. HPV 59 prevalence followed a linear trend, with
increased odds in 2012 (OR 16.0, 95% CI 3.8–67.3; Bonferroni-adjusted p-value <0.01).
Conclusions: The prevalences of HR-HPV 58, 59, and 68 were high in this cohort. Given current HR-HPV
vaccine coverage and availability, further investigations are needed to optimize vaccine recommenda-
tions for this population.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
HIV-infected women are at increased risk of human papillo-
mavirus (HPV)-associated invasive cervical carcinoma (ICC),1 an
AIDS-deﬁning illness and vaccine-preventable disease. Despite
routine screening in Brazil, the Instituto Nacional de Caˆncer
estimated 15,590 new ICC cases in 2014, with a 33% fatality rate.
High-risk HPV (HR-HPV) genotypes 16 and 18 are associated with* Corresponding author. Tel.: +1 310 854 9474.
E-mail address: mcambou@monteﬁore.org (M.C. Cambou).
http://dx.doi.org/10.1016/j.ijid.2015.10.017
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).70% of ICC cases worldwide, while the other 13 HR-HPV genotypes
account for the remaining cases.2
The HPV vaccine was proposed as a method to effectively
reduce ICC prevalence at the population level. Three US Food and
Drug Administration (FDA)-approved HR-HPV vaccines are cur-
rently available: the bivalent, quadrivalent, and nine-valent
vaccines. The bivalent and quadrivalent vaccines protect against
only HPV 16 and 18 of the HR-HPV genotypes, and the impact of
these vaccines on non-16/18 HR-HPV genotypes remains un-
clear.3–5 Non-16/18 HR-HPV genotypes are detected at higher rates
in HIV-infected women,2 and it is uncertain whether a single
sample traditionally used in cross-sectional studies accuratelyciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
M.C. Cambou et al. / International Journal of Infectious Diseases 41 (2015) 17–2018captures HPV infection patterns in this population. A time trend
analysis of annual cervical HR-HPV genotype prevalences from
2006 to 2012 among a non-vaccinated, HIV-positive female cohort
in urban Brazil was performed to establish a pre-vaccine baseline.
2. Methods
2.1. Data collection
An annual, cross-sectional analysis of participants in the Evandro
Chagas Clinical Research Institute (IPEC) Women’s HIV Cervical HPV
Genotyping Study at Fiocruz (Rio de Janeiro, Brazil) was conducted.
Cohort procedures have been published previously.6 Participants in
the IPEC Women’s HIV Cohort (est. 1996) aged 18 years were
invited to participate in the IPEC Women’s HIV Cervical HPVTable 1
Annual characteristics of participants in the IPEC Women’s HIV Cervical HPV Genotypi
2006 2007 2008 
N = 590 102 167 240 
First appointmenta 75 (74%) 55 (33%) 69 (29%) 
Age, years
Median (IQR) 35.5 (29.3–42.0) 36.0 (30.0–43.0) 37.0 (30.8–44.3) 
<30 26 (25%) 40 (24%) 53 (22%) 
30–39 41 (40%) 61 (37%) 88 (37%) 
40–49 28 (27%) 51 (31%) 72 (30%) 
50 7 (7%) 15 (9%) 27 (11%) 
Unknown 0 (0%) 0 (0%) 0 (0%) 
Current CD4 count, cells/mm3
>350 55 (54%) 96 (57%) 156 (65%) 
350 31 (30%) 58 (35%) 71 (30%) 
Unknown 16 (16%) 13 (8%) 13 (5%) 
Current HIV viral load, copies/mlb
Detectable 45 (44%) 79 (47%) 98 (41%) 
Undetectable 35 (34%) 60 (36%) 121 (50%) 
Unknown 22 (22%) 28 (17%) 21 (9%) 
Cervical cytology
Negative 77 (75%) 130 (78%) 190 (79%) 
ASC-US 10 (10%) 12 (7%) 26 (11%) 
AGC 0 (0%) 1 (<1%) 0 (0%) 
ASC-H 0 (0%) 0 (0%) 0 (0%) 
LSIL 15 (15%) 18 (11%) 21 (9%) 
HSIL 0 (0%) 4 (2%) 2 (<1%) 
Cervical cancer 0 (0%) 0 (0%) 1 (<1%) 
Unknown 0 (0%) 2 (1%) 0 (0%) 
Cervical treatment
Hysterectomy 0 (0%) 0 (0%) 0 (0%) 
Cone 1 (1%) 1 (<1%) 2 (<1%) 
Cauterization 0 (0%) 0 (0%) 0 (0%) 
LEEP 4 (4%) 4 (2%) 5 (2%) 
Any HPV
1 HPV 72 (71%) 88 (53%) 135 (56%) 
No HPV 30 (29%) 79 (47%) 105 (44%) 
HR-HPV genotype prevalence (%)
16 25 13 10 
18 12 13 7 
31 11 7 3 
33 1 7 5 
35 6 7 9 
39 10 3 4 
45 4 6 5 
51 7 5 5 
52 6 7 9 
56 10 7 4 
58 25 13 12 
59 2 7 8 
68 24 8 5 
73 0 4 5 
82 1 2 2 
IPEC, Evandro Chagas Clinical Research Institute; HPV, human papillomavirus; IQR, inter
Atypical glandular cells; ASC-H, Atypical squamous cells; LSIL, Low-grade squamous in
electrosurgical excision procedure; HR, high-risk.
a Ninety of the 590 women had their ﬁrst appointment in 2005.
b Detectable deﬁned as 400 copies/ml for 2006–2010, and 50 copies/ml for 2011Genotyping Study. On-site gynecologists collected specimens for
cytology and HPV genotyping yearly. Cervical HPV genotyping and
cytology analysis procedures have been published previously.7 The
IPEC Women’s HIV Cervical HPV Genotyping Study was approved by
the Institutional Review Board of IPEC at Fiocruz, Rio de Janeiro,
Brazil. Written informed consent was obtained from all participants
prior to enrollment and initiation of study procedures.
2.2. Statistical analysis
A descriptive analysis of the following was performed yearly
(2006–2012), using clinical data and cervical specimens closest to
the July 1 marker of the mid-year: current age, CD4+ T-cell count,
HIV-1 viral load, cervical cytology, cervical treatments, and
prevalences of the 15 HR-HPV genotypes. The clinical data forng Study at the time of cervical specimen collection (2006–2012)
2009 2010 2011 2012
282 256 260 225
105 (37%) 71 (28%) 59 (23%) 66 (29%)
36.5 (31.0–45.8) 38.0 (31.0–46.0) 38.0 (31.0–46.0) 40.0 (32.0–47.0)
60 (21%) 51 (20%) 56 (22%) 39 (17%)
110 (39%) 86 (34%) 84 (32%) 71 (32%)
74 (26%) 80 (31%) 77 (30%) 74 (33%)
38 (13%) 39 (15%) 42 (16%) 41 (18%)
0 (0%) 0 (0%) 1 (<1%) 0 (0%)
201 (71%) 178 (70%) 193 (74%) 172 (77%)
59 (21%) 56 (22%) 46 (18%) 40 (18%)
22 (8%) 22 (8%) 21 (8%) 13 (5%)
106 (38%) 79 (31%) 103 (40%) 83 (37%)
136 (48%) 146 (57%) 129 (50%) 125 (56%)
40 (14%) 31 (12%) 28 (10%) 17 (7%)
200 (71%) 193 (75%) 187 (72%) 179 (80%)
29 (10%) 24 (9%) 28 (10%) 21 (9%)
0 (0%) 1 (<1%) 2 (1%) 0 (0%)
0 (0%) 0 (0%) 0 (0%) 0 (0%)
42 (15%) 34 (13%) 33 (13%) 23 (10%)
8 (3%) 2 (1%) 7 (3%) 1 (<1%)
0 (0%) 0 (0%) 0 (0%) 0 (0%)
3 (1%) 2 (1%) 3 (1%) 1 (<1%)
0 (0%) 0 (0%) 0 (0%) 1 (<1%)
3 (1%) 3 (1%) 4 (2%) 3 (1%)
4 (1%) 6 (2%) 5 (2%) 4 (2%)
2 (<1%) 1 (<1%) 2 (1%) 0 (0%)
170 (60%) 180 (70%) 187 (72%) 159 (71%)
112 (40%) 76 (30%) 73 (28%) 66 (29%)
12 12 15 12
6 11 7 8
7 8 9 12
5 6 4 3
9 11 13 13
6 7 7 12
7 5 4 10
8 13 15 7
6 6 8 6
5 5 5 11
19 20 26 21
7 11 19 24
5 8 9 10
4 5 3 7
1 3 2 5
quartile range; ASC-US, Atypical squamous cells of undetermined signiﬁcance; AGC,
traepithelial lesion; HSIL, High-grade squamous intraepithelial lesion; LEEP, loop
–2012, based on assays used.
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sample in that given year. Women who underwent hysterectomies
were excluded from the analysis in the years post-procedure.
Odds ratios (OR) and 95% conﬁdence intervals (CI) for HPV
positivity were estimated for each genotype using generalized
estimating equation models with an exchangeable matrix to
account for patient clustering. The year was the independent
predictor, with 2006 as the reference category. The ﬁnal model was
adjusted for age as a continuous variable, given the inverse
association between age and HPV positivity.8 Bonferroni-adjusted
p-values were calculated to account for multiple comparisons. The
statistical analysis was performed using R version 3.01, with
statistical signiﬁcance deﬁned using a two-sided a < 0.05.
3. Results
Five hundred ninety-one women met the inclusion criteria,
with one excluded for prior hysterectomy (ﬁnal N = 590). Table 1
describes the characteristics and annual HR-HPV genotype
prevalences by year (2006–2012). Table 2 provides ORs for HR-
HPV positivity in those years. The prevalences of HR-HPV 16, 58,
59, and 68 were 24% in at least 1 year, while the prevalence of
HPV 18 never surpassed 13%. The odds of HPV 16 and 68 decreased
signiﬁcantly in 2012 compared to 2006, starting with prevalences
of 25% and 24% for HPV 16 and 68, respectively, and ending with
12% and 10%. While the odds of HPV 58 decreased from 25% in
2006 to 12% in 2008, it rebounded to 21% by 2012. The odds of HPV
59 increased 16-fold between 2006 and 2012, with prevalence
increasing from 2% to 24%.
4. Discussion
In this cohort of 590 HIV-positive women, the high prevalences
of HPV 58 and 59 are concerning, given that HPV 58 is associated
with pre-malignant cervical lesions among HIV-uninfected women
in Brazil,9,10 and both genotypes are commonly identiﬁed in
HIV-positive women worldwide.2 Additionally, neither the biva-
lent nor the quadrivalent vaccine cover HPV 58 and 59, leading to
questions regarding their efﬁcacy against non-16/18 genotypes.4,5
This study has both strengths and limitations. While it is
unclear which factors inﬂuenced the ﬂuctuating HPV prevalences,
current clinical and cervical data remained relatively unchanged.
HPV prevalences were analyzed over a 7-year period, compared to
most studies utilizing a single time point. Additionally, the present
study is one of the largest HPV/HIV co-infection studies in the
Americas. However, the individual sample sizes for each HPV
genotype are relatively small, and additional studies with larger
sample sizes and longer follow-up are needed to further explore
temporal trends in HR-HPV prevalences.
Continued monitoring of HR-HPV epidemiology and further
investigations into the effects of HPV vaccination on non-16/18
HR-HPV genotypes are needed to optimize HPV vaccine recom-
mendations for HIV-infected women in Brazil.
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